Table 1. Baseline characteristics of patients with ALK-positive advanced non-small cell lung cancer.
| Variables | Value |
|---|---|
| Age, years | 54.5 [53–78] |
| Sex | |
| Male | 47 (49.0) |
| Female | 49 (51.0) |
| Smoking history | |
| Current | 14 (14.6) |
| Former | 18 (18.8) |
| Never | 64 (66.7) |
| ECOG performance status | |
| 0 | 12 (16.4) |
| 1 | 59 (80.8) |
| 2 | 2 (2.7) |
| Pathologic diagnosis | |
| Adenocarcinoma | 93 (96.9) |
| Othera | 3 (3.1) |
| Brain metastasis | |
| Present | 59 (62.8) |
| Absent | 35 (37.2) |
| EML4-ALK fusion variant | |
| V1 | 27 (37.0) |
| V2 | 10 (13.7) |
| V3a/b | 33 (45.2) |
| V5 | 2 (2.7) |
| V7 | 1 (1.4) |
| Prior lines of therapy before ALK inhibitor | |
| 0 | 54 (56.3) |
| 1 | 34 (35.4) |
| 2 | 6 (6.3) |
| ≥3 | 2 (2.1) |
| Prior platinum-based therapy | |
| Present | 40 (41.7) |
| Absent | 56 (58.3) |
| Total | 96 (100.0)b |
Data are presented as median (range) or n [%]. a, includes large cell neuroendocrine carcinoma, squamous cell carcinoma, and non-small cell carcinoma, not-otherwise specified; b, some variables did not reach 96 due to the non-availability of data. ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group.